Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation

Moleculin Biotech, Inc. (NASDAQ:MBRX) has received a delisting notice from the Nasdaq Stock Market LLC due to a violation of the exchange's minimum bid price requirement. The company's stock price fell below $1.00 per share for 30 consecutive business days from July 31, 2026 to September 11, 2026, which is in breach of Nasdaq Listing Rule 5550(a)(2).

Typically, companies that fall below this minimum bid price are given 180 days to regain compliance. However, Moleculin is not eligible for this period as it had a 1-for-25 reverse stock split earlier in the year, effective December 1, 2025. The company's stock is currently trading at $0.77, a 92% decline from its 52-week high of $15.75 over the past year.

Moleculin plans to request a hearing before the Nasdaq Hearings Panel to stay any suspension or delisting action. However, there is no guarantee that this request will be approved, and the company may still struggle to comply with Nasdaq's rules. This situation follows the announcement of positive interim data from Moleculin's Phase 2/3 MIRACLE trial, which evaluated the effectiveness of Annamycin in treating relapsed or refractory acute myeloid leukemia.